Harold DMD - NervGen Pharma CoFounder Director

NGEN Stock

CAD 2.87 0.08 2.87%

Insider

Harold DMD is CoFounder Director of NervGen Pharma Corp

Address	112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4
Phone	778 731 1711
Web	https://www.nervgen.com

NervGen Pharma Management Efficiency

The company has return on total asset (ROA) of (0.5314) % which means that it has lost $0.5314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.3027) %, meaning that it generated substantial loss on money invested by shareholders. NervGen Pharma's management efficiency ratios could be used to measure how well NervGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NervGen Pharma's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 11.70 in 2024, whereas Return On Tangible Assets are likely to drop (1.85) in 2024. Intangibles To Total Assets is likely to climb to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 11.3 M in 2024.

Compare NervGen Pharma to Peers

Predict price of NervGen Pharma

NervGen Pharma Corp has accumulated 15.25 M in total debt. NervGen Pharma Corp has a current ratio of 25.21, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist NervGen Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, NervGen Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NervGen Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NervGen to invest in growth at high rates of return. When we think about NervGen Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Larry Page	Alphabet Inc CDR	51
	Jeffrey Williams	Apple Inc CDR	60
	Amie OToole	Alphabet Inc CDR	49
	Werner Vogels	Amazon CDR	N/A
	Russell Miller	Costco Wholesale Corp	67
	Luca Maestri	Apple Inc CDR	61
	Robert III	Costco Wholesale Corp	N/A
	Satya Nadella	Microsoft Corp CDR	57
	Kent Walker	Alphabet Inc CDR	63
	Frank Shaw	Microsoft Corp CDR	N/A
	Steven Kessel	Amazon CDR	58
	Mary Demby	Apple Inc CDR	N/A
	Fiona Cicconi	Alphabet Inc CDR	58
	James Wilson	Apple Inc CDR	N/A
	Christopher Capossela	Microsoft Corp CDR	54
	Nancy Paxton	Apple Inc CDR	N/A
	Dave Fildes	Amazon CDR	N/A
	Anuradha Aggarwal	Amazon CDR	N/A
	Timothy Cook	Apple Inc CDR	63
	John Thelan	Costco Wholesale Corp	N/A
	Shelley Reynolds	Amazon CDR	59

NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange. NervGen Pharma Corp (NGEN) is traded on TSX Venture Exchange in Canada and employs 7 people. NervGen Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-2.3
	Return On Asset	-0.53

NervGen Pharma Corp Leadership Team

Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Brian McAlister, CoFounder Advisor
	Harold DMD, CoFounder Director
	Elizabeth BSc, Senior Management
	Michael Kelly, President CEO
	Adam MD, Interim Director
	Charles DSc, Senior Operations
	William BASc, CoFounder Chairman

NervGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NervGen Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-2.3
	Return On Asset	-0.53
	Current Valuation	180.91 M
	Shares Outstanding	70.31 M
	Shares Owned By Insiders	22.91 %
	Shares Owned By Institutions	0.06 %
	Number Of Shares Shorted	199.54 K
	Price To Book	21.99 X
	EBITDA	(19.24 M)
	Net Income	(22.38 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC